Inositol levels are decreased in postmortem brain of schizophrenic patients

Biological Psychiatry

Volumn 44, Issue 6, 1998, Pages 428-432

  Shimon, Hady ^a   Sobolev, Yelena ^a   Davidson, Michael ^b   Haroutunian, Varham ^c,d   Belmaker, Robert H ^a   Agam, Galila ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Inositol levels; Postmortem brain; Schizophrenic patients

Indexed keywords

INOSITOL; LITHIUM; MYOINOSITOL 1 PHOSPHATE SYNTHASE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; ENZYME ACTIVITY; ENZYME ANALYSIS; GAS CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDROLYSIS; NEUROPATHOLOGY; PHOSPHATE METABOLISM; PRIORITY JOURNAL; SCHIZOPHRENIA;

AGED; AGED, 80 AND OVER; BRAIN; BRAIN CHEMISTRY; FEMALE; HUMANS; INOSITOL; MALE; MIDDLE AGED; PHOSPHORIC MONOESTER HYDROLASES; SCHIZOPHRENIA;

EID: 0032530495     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(98)00071-7     Document Type: Article

References (36)

1. + concentrations. Psychiatry Res. 27:1989;217-224.
2. Allison J.H., Blisner M.E., Holland W.M., Hipps P.P., Sherman W.B. Increased myo-inositol-1-phosphate in lithium-treated rats. Biochem Biophys Res Commun. 71:1976;664-670.
3. Atack J.R. Inositol monophosphatase, the putative therapeutic target for lithium. Brain Res Rev. 22:1996;183-190.
4. Belmaker RH, Agam G, van Calker D, Richards MH, Kofman O (in press): Behavioral reversal of lithium effects by four inositol isomers correlates perfectly with biochemical effects on the PI cycle; depletion by chronic lithium of brain inositol is specific to hypothalamus; and inositol levels may be abnormal in post-mortem brain for bipolar patients. Neuropsychopharmacology.
5. Benjamin J., Levine J., Fux M., Aviv A., Levy D., Belmaker R.H. Inositol treatment for panic disorder A double-blind placebo-controlled crossover trial . Am J Psychiatry. 152:1995;1084-1086.
6. Berridge M.J., Downes C.P., Hanley R.R. Neural and developmental action of lithium A unifying hypothesis . Cell. 59:1989;411-419.
7. Davidson M., Harvey P.D., Powchik P., et al. Severity of symptoms in chronically institutionalized geriatric schizophrenic patients. Am J Psychiatry. 152:1995;197-207.
8. 31Phosphorus magnetic response spectroscopy of the frontal and parietal lobes in chronic schizophrenia. Biol Psychiatry. 36:1994;503-510.
9. Deicken R.F., Fein G., Weiner M.W. Abnormal frontal lobe phosphorus metabolism in bipolar disorder. Am J Psychiatry. 152:1995;915-918.
10. Fux M., Levine J., Aviv A., Belmaker R.H. Inositol treatment of obsessive-compulsive disorder. Am J Psychiatry. 153:1996;1219-1221.
11. Gyulai L., Bolinger L., Leigh J.S., Barlow C., Chance B. Phosphorylethanolamine The major constituent of the phosphomonoester peak observed by P-31 NMR of developing dog brain . FEBS Lett. 178:1984;137-142.
12. Hardy J.A., Wester P., Winblad B., Gezelius C., Bring G., Eriksson A. Patients dying after long terminal phase have acidotic brains Implications for biochemical measurements on autopsy tissue . J Neural Transm Gen Sect. 61:1985;253-264.
13. Harrison P.J. Advances in post mortem molecular neurochemistry and neuropathology Examples from schizophrenia research . Br Med Bull. 52:1996;527-538.
14. Haussinger D., Laubenberger J., Dahl V., et al. Proton magnetic resonance spectroscopy studies on human brain myo-inositol in hypo-osmolarity and hepatic encephalopathy. Gastroenterology. 107:1994;1475-1480.
15. Hertz L, Wolfson M, Hertz E, Agam G, Richards M, Belmaker RH (in press): Lithium-inositol interactions. In: Honig A, Ansseau M, van Praag HM, editors. Depression: Neurobiological, Psychopathological and Therapeutic Advances. Chichester, U.K.: Wiley.
16. Kerwin R.W., Beats B.C. Increased forskolin binding in the left parahippocampal gyrus and CA1 region in post mortem schizophrenic brain determined by quantitative autoradiography. Neurosci Lett. 118:1990;164-168.
17. 31P nuclear magnetic resonance (NMR) spectroscopy of the frontal lobe metabolism in neuroleptic naive first episode psychoses Preliminary studies . Schizophr Res. 2:1989;122.
18. Levine J., Goldberger I., Rapaport A., et al. CSF inositol levels in schizophrenia are unchanged and inositol is not therapeutic in anergic schizophrenia. Eur Neuropsychopharmacol. 4:1994;487-490.
19. Levine J., Barak Y., Gonsalves M., et al. A double-blind controlled trial of inositol treatment of depression. Am J Psychiatry. 152:1995;792-794.
20. Nishino N., Kitamura N., Hashimoto T., et al. Increase in [3H] cAMP binding sites and decrease in Gi alpha and Go alpha immunoreactivities in left temporal cortices from patients with schizophrenia. Brain Res. 615:1993;41-49.
21. 31P magnetic resonance spectroscopy. Biol Psychiatry. 29:1991;1129-1148.
22. Okada F., Crow T.J., Roberts G.W. G proteins (Gi, Go) and the basal ganglia of control and schizophrenic brain. J Neural Transm Gen Sect. 79:1990;227-234.
23. Okada F., Tokumitsu T., Asano K., et al. Low amounts of the α-subunit of GTP-binding protein Go in orbital frontal cortex of schizophrenic brain Biochemical evidence of the hypofrontality hypothesis of schizophrenia . Schizophr Res. 4:1991;353-354.
24. Okada F., Tokumitsu Y., Takahashi N., Crow T.J., Roberts G.W. Reduced concentrations of the alpha-subunit of GTP-binding protein Go in schizophrenic brain. J Neural Transm Gen Sect. 95:1994;95-104.
25. 1H-magnetic resonance spectroscopy of postmortem brains with schizophrenia. Biol Psychiatry. 42:1997;359-366.
26. Palmer A.M., Lowe S.L., Francis P.T., Bowen D.M. Are post-mortem biochemical studies of human brain worthwhile? Biochem Soc Trans. 16:1988;472-475.
27. Patishi Y., Belmaker R.H., Agam G. Effect of age, sex, steroids, brain region and genetic strain on brain inositol monophosphatase activity. Biol Psychiatry. 40:1996;656-659.
28. Pettegrew J.W., Keshavan M., Panchalingam K., et al. Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode, drug-naive schizophrenics. Arch Gen Psychiatry. 48:1991;563-568.
29. Preece N.E., Gadian D.G., Houseman J., Williams S.R. Lithium-induced modulation of cerebral inositol phosphate metabolism in the rat A multinuclear magnetic resonance study in vivo . Lithium. 3:1992;287-297.
30. Purohit D.P., Davidson M., Perl D.P., et al. Severe cognitive impairments in elderly schizophrenic patients A clinicopathological study . Biol Psychiatry. 33:1993;255-260.
31. 2 dopamine receptors is reduced in schizophrenia and Huntington diseased brain. Proc Natl Acad Sci USA. 86:1989;10156-10160.
32. Sherman W.R., Leavitt A.L., Honchar M.P., Hallcher L.M., Phillips B.E. Evidence that lithium alters phosphoinositide metabolism Chronic administration elevates primarily D-myo-inositol-1-phosphate in cerbral cortex of the rat . J Neurochem. 36:1981;1947-1951.
33. Shimon H., Agam G., Belmaker R.H., Hyde T., Kleinman J.E. Reduced inositol levels in frontal cortex of post-mortem brain from bipolar patients and suicides. Am J Psychiatry. 154:1997;1148-1150.
34. Williamson P., Drost D., Stanley J., Carr T., Morrison S., Merskey H. Localized phosphorous 31 magnetic resonance spectroscopy in chronic schizophrenic patients and normal controls [letter]. Arch Gen Psychiatry. 48:1991;578.
35. Woods B.T., Yurgelun-Todd D., Benes F.M., Frankenburg F.R., Pope H.G. Jr, McSparren J. Progressive ventricular enlargement in schizophrenia Comparison to bipolar affective disorder and correlation with clinical course . Biol Psychiatry. 27:1990;341-352.
36. Zilberman-Kaufman M., Agam G., Moscowitz L., Livne A.A., Belmaker R.H. Raised monophosphatase activity in schizophrenic patients. Clin Chem Acta. 209:1992;89-93.